Surv-CRM

Survival-Continual Reassessment Method (Surv-CRM)

The Surv-CRM is a Phase I design built on the CRM dose-finding design, using survival models to handle right-censored DLT endpoints allowing the outcomes to be delayed.

Article reference: Andrillon, A., Chevret, S., Lee, S. M., & Biard, L. (2020). Dose-finding design and benchmark for a right censored endpoint. Journal of biopharmaceutical statistics, 30(6), 948–963.
https://doi.org/10.1080/10543406.2020.1821702

Clinical trial parameters

Download the patients file
A 4-column dataframe containing patient identifiers, outcomes with 1 indicates a toxicity, 0 otherwise, time to failure due to toxicity or time to end of follow-up (in days)

Upload data file using this csv file template

Browse...

Enter the clinical trial parameters

The target toxicity probability of DLT

Number of candidate doses

Initial dose

Sample size of the trial

End of the toxicity obs window (in days)

The prior guess of MTD

The desired halfwidth of the indifference intervals

No_pat_at_least

Dose assignment
Data summary